Avalo Therapeutics AVTX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$19.63M-43.1% | -$13.72M+55.2% | -$30.63M-47.5% | -$20.77M-57.9% | -$13.15M+62.8% | ||
| $17K+6.3% | $16K-72.9% | $59K-56.0% | $134K-0.7% | $135K+98.5% | ||
| $3.58M-20.7% | $4.51M+42.9% | $3.15M+16.0% | $2.72M-16.1% | $3.24M+11.6% | ||
| $12K-90.8% | $131K+1,210% | $10K-37.5% | $16K+100% | $8K-93.0% | ||
| $219K+165% | -$337K+82.2% | -$1.89M-212% | $1.69M+323% | $398K+126% | ||
| -$1.5M-128% | $5.35M+425% | $1.02M-48.8% | $1.99M+217% | -$1.7M— | ||
| -$228K-105% | $4.77M— | —— | —— | -$2.49M— | ||
| -$17.69M-24.2% | -$14.25M+12.9% | -$16.37M-43.7% | -$11.39M-20.4% | -$9.46M+37.1% | ||
| $25.51M— | —— | —— | —— | $0— | ||
| $25.51M— | $0+100% | -$13.26M+81.3% | -$70.86M— | $0— | ||
| $2.18M-85.2% | $14.72M— | $0-100% | $40K— | $0— | ||
| $779K— | $0-100% | $1K-99.8% | $509K— | $0— | ||
| $1.4M+104% | $687K-95.2% | $14.37M+3,164% | -$469K— | $0-100% | ||
| $9.21M+183% | -$11.16M+26.9% | -$15.26M+81.6% | -$82.72M-775% | -$9.46M-118% | ||
| $106K-46.2% | $197K-43.2% | $347K+138% | $146K— | $0— | ||
| $480K+102% | -$24.2M-293% | $12.53M+395% | $2.53M+566% | $380K+104% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| -$31K+50.8% | -$63K-65.8% | -$38K-643% | $7K0.0% | $7K+200% | ||
| -$1.5M-128% | $5.35M+425% | $1.02M-48.8% | $1.99M+217% | -$1.7M— | ||
| -$228K-105% | $4.77M— | —— | —— | -$2.49M— | ||
| $0— | —— | —— | —— | $509K— | ||
| $25.51M— | —— | —— | —— | $0— | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| —— | $115.5K0.0% | $115.5K0.0% | $115.5K0.0% | $115.5K— | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $0— | $0— | $0-100% | $509K+200% | -$509K— | ||
| —— | $0— | $0— | $0— | $0-100% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Avalo Therapeutics generate?
- Avalo Therapeutics (AVTX) generated -$59.7M in operating cash flow over the trailing twelve months.
- Where does Avalo Therapeutics's cash flow data come from?
- Every line is extracted from Avalo Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
